Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 250mg;  ;   - dispersible tablet - 250 mg - active: deferasirox 250mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 500mg;  ;   - dispersible tablet - 500 mg - active: deferasirox 500mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - metoprolol tartrate 100mg - tablet - 100 mg - active: metoprolol tartrate 100mg excipient: colloidal silicon dioxide hypromellose indigo carmine magnesium stearate microcrystalline cellulose povidone purified water shellac sodium starch glycolate titanium dioxide - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - metoprolol tartrate 50mg - tablet - 50 mg - active: metoprolol tartrate 50mg excipient: colloidal silicon dioxide hypromellose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose polysorbate 80 povidone purified talc sodium starch glycolate titanium dioxide - disturbances of cardiac rhythm, including supraventricular and ventricular arrhythmias.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - basiliximab 10mg (murine/human; formulated with a 7.5% total overage);   - powder for injection - 10 mg - active: basiliximab 10mg (murine/human; formulated with a 7.5% total overage)   excipient: dibasic sodium phosphate glycine mannitol monobasic potassium phosphate sodium chloride sucrose water for injection - simulect is indicated for the prophylaxis of acute organ rejection in de novo renal transplantation in adult and paediatric patients. it is to be used concomitantly with cyclosporin for microemulsion- and corticosteroid-based immunosuppression or in a triple maintenance immunosuppressive regimen containing cyclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - basiliximab 20mg (murine/human; formulated with a 7.5% total overage) - powder for injection - 20 mg - active: basiliximab 20mg (murine/human; formulated with a 7.5% total overage) excipient: dibasic sodium phosphate glycine mannitol monobasic potassium phosphate sodium chloride sucrose water for injection - simulect is indicated for the prophylaxis of acute organ rejection in de novo renal transplantation in adult and paediatric patients. it is to be used concomitantly with cyclosporin for microemulsion- and corticosteroid-based immunosuppression or in a triple maintenance immunosuppressive regimen containing cyclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 25mg;  ;   - enteric coated tablet - 25 mg - active: diclofenac sodium 25mg     excipient: ammonia solution colloidal silicon dioxide hypromellose   silicone antifoam emulsion (enteric-coat)   pigment suspension white   pigment suspension white (colour-coat) lactose monohydrate macrogol 8000 magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil   povidone purified talc     purified water     sodium starch glycolate - treatment of: inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; acute attacks of gout; post-traumatic and postoperative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac sodium 50mg;  ;   - enteric coated tablet - 50 mg - active: diclofenac sodium 50mg     excipient: colloidal silicon dioxide hypromellose   silicon antifoam emulsion se2, enteric coat iron oxide red   iron oxide yellow   lactose monohydrate macrogol 8000 magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose polyethylene glycol hydrogenated castor oil   povidone purified talc   sodium starch glycolate titanium dioxide   - treatment of: inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; acute attacks of gout; post-traumatic and postoperative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - diclofenac 46.5mg (as free acid = 50mg diclofenac sodium);   - dispersible tablet - 50 mg - active: diclofenac 46.5mg (as free acid = 50mg diclofenac sodium)   excipient: colloidal silicon dioxide croscarmellose sodium hydrogenated castor oil microcrystalline cellulose purified talc sodium starch glycolate - latest regulatory activity

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - rivastigmine tartrate 0.8mg equivalent to 0.5 mg rivastigmine - capsule - 0.5 mg - active: rivastigmine tartrate 0.8mg equivalent to 0.5 mg rivastigmine excipient: colloidal silicon dioxide gelatin   hypromellose iron oxide red iron oxide yellow   magnesium stearate microcrystalline cellulose opacode brown s-1-9460hv titanium dioxide